Arcus Biosciences, Inc.
Description
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.
About
CEO
Dr. Terry J. Rosen Ph.D.
Employees
577
Instrument type
Common Stock
Sector
Healthcare
Industry
Biotechnology
MIC code
XNYS
Address
3928 Point Eden Way, Hayward, CA 94545, United States
×
![Enlarged Chart]()
Oscillators
Invalid data format
Summary
Invalid data format
Moving Averages
Invalid data format
Earnings
| Date | Estimate EPS | Actual EPS | Difference | % Surprise |
|---|---|---|---|---|
| Nov 4, 2025 | — | — | — | — |
| Aug 5, 2025 | — | — | — | — |
| May 6, 2025 | — | — | — | — |
| Feb 19, 2025 | -1.20 | — | — | — |
| Nov 7, 2024 | -1.06 | -1.00 | 0.06 | -5.66% |
Earnings estimate
|
Next Quarter
(Mar 2025)
|
Next Year
(Dec 2025)
|
|||
|---|---|---|---|---|
| Number of analysts | — | 2 | — | 7 |
| Average estimate | — | -1.06 | — | -3.66 |
| Low estimate | — | -1.23 | — | -5.43 |
| High estimate | — | -0.89 | — | 0.06 |
| Last year EPS | — | 0.19 | — | -3.16 |
[stock_revenue_estimate]
Growth estimates
Current qtr
-11.400%
Next qtr. (Mar 2025)
-671.120%
Current year
23.890%
Next year (Dec 2025)
-15.980%
Next 5 years (per annum)
—
Past 5 years (per annum)
—
Income statement
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Fiscal date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total reported revenue | 117.00M | 112.00M | 383.00M | 78.00M | 15.00M |
| Cost of revenue | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating expense | |||||
| Research & development | 340.00M | 288.00M | 257.00M | 159.00M | 78.48M |
| Selling general and admin | 117.00M | 104.00M | 72.00M | 43.00M | 25.23M |
| Other operating expenses | — | — | — | — | — |
| Operating income | -340.00M | -280.00M | 54.00M | -124.00M | -88.71M |
| Non operating interest income | |||||
| Income | 41.00M | 16.00M | 1.00M | 1.00M | 5.20M |
| Expense | 2.00M | 2.00M | — | — | — |
| Other income expense | — | — | — | — | -1.20M |
| Pretax income | -301.00M | -266.00M | 55.00M | -123.00M | -84.71M |
| Tax provision | 6.00M | 1.00M | 2.00M | — | — |
| Net income | -307.00M | -267.00M | 53.00M | -123.00M | -84.71M |
| Basic EPS | -4.15 | -3.71 | 0.76 | -2.24 | -1.93 |
| Diluted EPS | -4.15 | -3.71 | 0.71 | -2.24 | -1.93 |
| Basic average shares | 74.00M | 72.00M | 69.35M | 54.79M | 43.83M |
| Diluted average shares | 74.00M | 72.00M | 69.35M | 54.79M | 43.83M |
| EBITDA | -291.00M | -258.00M | 59.00M | -120.00M | -81.13M |
| Net income from continuing op. | -307.00M | -267.00M | 53.00M | -123.00M | -84.71M |
| Minority interests | — | — | — | — | — |
| Preferred stock dividends | — | — | — | — | — |
Balance sheet
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Fiscal date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 1.10B | 1.35B | 1.59B | 772.29M | 203.11M |
| Current assets | |||||
| Cash | — | — | — | — | — |
| Cash equivalents | — | — | — | — | — |
| Cash and cash equivalents | 127.00M | 206.00M | 148.00M | 173.42M | 57.94M |
| Other short term investments | 632.00M | 803.00M | 351.00M | 555.23M | 130.33M |
| Accounts receivable | 38.00M | 39.00M | 745.00M | 1.05M | 132,000 |
| Other receivables | — | — | — | — | — |
| Inventory | — | — | — | — | — |
| Prepaid assets | — | 15.00M | 16.00M | 5.47M | 4.05M |
| Restricted cash | — | — | — | — | — |
| Assets held for sale | — | — | — | — | — |
| Hedging assets | — | — | — | — | — |
| Other current assets | 30.00M | 15.00M | 16.00M | 5.47M | 4.05M |
| Non current assets | |||||
| Properties | 24.00M | 17.00M | 14.00M | 22.68M | 8.17M |
| Land and improvements | — | — | — | — | — |
| Machinery furniture equipment | 3.00M | 3.00M | 2.00M | 1.75M | 1.31M |
| Construction in progress | 1.00M | 4.00M | 2.00M | 2.34M | 238,000 |
| Leases | 54.00M | 34.00M | 32.00M | 11.11M | 10.83M |
| Accumulated depreciation | -31.00M | -23.00M | -18.00M | -14.29M | -11.22M |
| Goodwill | — | — | — | — | — |
| Investment properties | — | — | — | — | — |
| Financial assets | — | — | — | — | — |
| Intangible assets | — | — | — | — | — |
| Investments and advances | 107.00M | 129.00M | 182.00M | 6.44M | — |
| Other non current assets | 106.00M | 114.00M | 116.00M | 6.45M | 1.08M |
| Total liabilities | 633.00M | 688.00M | 750.00M | 269.99M | 39.27M |
| Current liabilities | |||||
| Accounts payable | 17.00M | 20.00M | 10.00M | 15.68M | 4.70M |
| Accrued expenses | 62.00M | 70.00M | 52.00M | 27.85M | 9.52M |
| Short term debt | 11.00M | 3.00M | — | — | — |
| Deferred revenue | 91.00M | 97.00M | 102.00M | 74.57M | 7.00M |
| Tax payable | — | — | 2.00M | — | — |
| Pensions | — | — | — | — | — |
| Other current liabilities | 3.00M | 3.00M | 52,000 | 3.57M | 1.48M |
| Non current liabilities | |||||
| Long term debt | — | — | 116.89M | 15.24M | — |
| Provision for risks and charges | — | — | — | — | — |
| Deferred liabilities | — | — | — | — | — |
| Derivative product liabilities | — | — | — | — | — |
| Other non current liabilities | 142.00M | 140.00M | 122.00M | 543,000 | 806,000 |
| Shareholders equity | |||||
| Common stock | 1.31B | 1.21B | 1.12B | 6,000 | 4,000 |
| Retained earnings | -849.00M | -542.00M | -275.00M | -328.18M | -205.33M |
| Other shareholders equity | — | -7.00M | -1.00M | 44,000 | 64,000 |
| Total shareholders equity | 462.00M | 657.00M | 842.00M | 502.30M | 163.84M |
| Additional paid in capital | — | — | 1.12B | 830.44M | 369.10M |
| Treasury stock | — | — | — | — | — |
| Minority interest | — | — | — | — | — |
Cash flow statement
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | -307.00M | -267.00M | 53.00M | -123.00M | -84.71M | -49.59M | -53.08M | -17.97M |
| Depreciation | 8.00M | 6.00M | 4.00M | 3.00M | 3.58M | 3.66M | 2.61M | 1.31M |
| Deferred Taxes | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | 73.00M | 65.00M | 55.00M | 22.00M | 8.98M | 3.87M | 495,000 | 90,000 |
| Other Non-Cash Items | 10.00M | 11.00M | 3.00M | 1.00M | — | -177,000 | -98,000 | 90,000 |
| Accounts Receivable | 15.00M | 704.00M | -17.00M | -1.00M | -49,000 | -58,000 | 380,000 | — |
| Accounts Payable | -1.00M | 8.00M | -5.00M | 9.00M | 1.73M | -69,000 | -267,000 | 3.57M |
| Other Assets & Liabilities | -85.00M | -89.00M | -354.00M | 200.00M | -3.07M | -858,000 | 23.65M | -153,000 |
| Operating Cash Flow | -287.00M | 438.00M | -261.00M | 111.00M | -73.54M | -43.22M | -26.31M | -13.06M |
| Investing Activities | ||||||||
| Capital Expenditures | -24.00M | -6.00M | -26.00M | -3.00M | -1.93M | -3.74M | -5.51M | -4.10M |
| Net Intangibles | — | -3.00M | — | — | — | — | — | — |
| Net Acquisitions | — | — | — | — | — | — | — | -1.00M |
| Purchase of Investments | -788.00M | -1.24B | -719.00M | -740.00M | -247.76M | -261.55M | -96.83M | -33.76M |
| Sale of Investments | 1.01B | 837.00M | 741.00M | 309.00M | 308.89M | 151.86M | 53.27M | — |
| Investing Cash Flow | 194.00M | -410.00M | -4.00M | -434.00M | 59.21M | -113.44M | -49.07M | -39.86M |
| Financing Activities | ||||||||
| Long-Term Debt Issuance | — | — | — | — | — | — | — | — |
| Long-Term Debt Payments | — | — | — | — | — | — | — | — |
| Other Financing Charges | — | 10.00M | 5.00M | — | — | -135,000 | -373,000 | — |
| Financing Cash Flow | 25.00M | 10.00M | 224.99M | 433.95M | -94,000 | 124.98M | 106.50M | 69.82M |
| Other Cash Details | ||||||||
| End Cash Position | 130.00M | 209.00M | 151.00M | 174.00M | 58.14M | 71.27M | 98.43M | 65.16M |
| Income Tax Paid | — | 3.00M | — | — | — | — | — | — |
| Interest Paid | — | — | — | — | — | — | — | — |
| Free Cash Flow | -330.00M | 426.00M | -282.00M | 108.00M | -75.39M | -46.74M | -30.57M | -17.04M |
Top Institutional Holders
| Holder | Date Reported | Shares | Value | % Held |
|---|---|---|---|---|
| iShares Core S&P Smallcap ETF | Nov 30, 2024 | 3,476,736 | 47.18M | 3.80% |
| Fidelity Select Portfolios - Biotechnology | Nov 30, 2024 | 1,879,062 | 25.50M | 2.05% |
| Vanguard Total Stock Market Index Fund | Sep 30, 2024 | 1,616,463 | 21.94M | 1.77% |
| iShares Russell 2000 ETF | Nov 30, 2024 | 1,507,178 | 20.45M | 1.65% |
| SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF | Nov 30, 2024 | 919,193 | 12.47M | 1.00% |
| Vanguard Extended Market Index Fund | Sep 30, 2024 | 849,053 | 11.52M | 0.93% |
| Fidelity Select Portfolios - Pharmaceuticals | Nov 30, 2024 | 760,000 | 10.31M | 0.83% |
| Fidelity Select Portfolios - Health Care | Nov 30, 2024 | 700,000 | 9.50M | 0.76% |
| Vanguard Small-Cap Index Fund | Sep 30, 2024 | 630,221 | 8.55M | 0.69% |
| Fidelity Small Cap Index Fund | Oct 31, 2024 | 554,961 | 7.53M | 0.61% |
Article
Arcus Biosciences Announces New Employment Inducement Grants
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company's Board of Directors granted four new employees options to purchase a total of 31,800 shares of the Company's common stock at an exercise price per share of $13.33, which was the closing price on January 23, 2024, and.
Jan 24, 2025
Article
Arcus Biosciences Appoints Richard Markus, M.D., Ph.D. as Chief Medical Officer
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that Richard Markus, M.D., Ph.D., has been appointed chief medical officer (CMO) effective January 31, 2025. Dr. Markus replaces Dimitry Nuyten, M.D., Ph.D., who will be leaving the company at the end of January to pursue other opportunities. Dr. Markus's responsi.
Jan 21, 2025
Article
Arcus Biosciences: Many Important Oncology Catalysts Coming Up In 2025
Arcus Biosciences has interesting combination therapies that target several diseases like NSCLC, RCC, GI, and pancreatic cancers. The company has a few ongoing Phase 3 trials, some of which will report important updates in 2025. One of Domvanalimab's combinations showed that it can help overall survival by a whopping 36% in NSCLC. It also had lower discontinuation rates than chemotherapy.
Jan 15, 2025
